A randomized multicenter study with non-inferiority hypothesis, comparing the availability to maintain a complete viral suppression by a monotherapy of darunavir/r [ritonavir] to a NRTI [nucleoside reverse transcriptase inhibitor] containing regimen including darunavir/r, in HIV-1 infected patients with previous prolonged complete viral suppression. ANRS 136 MONOI

Trial Profile

A randomized multicenter study with non-inferiority hypothesis, comparing the availability to maintain a complete viral suppression by a monotherapy of darunavir/r [ritonavir] to a NRTI [nucleoside reverse transcriptase inhibitor] containing regimen including darunavir/r, in HIV-1 infected patients with previous prolonged complete viral suppression. ANRS 136 MONOI

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2013

At a glance

  • Drugs Darunavir (Primary) ; Nucleoside reverse transcriptase inhibitors; Ritonavir; Saquinavir
  • Indications HIV-1 infections
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Dec 2011 Primary endpoint 'Viral-load' has been met.
    • 08 Apr 2011 Actual end date (1 Feb 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top